FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093600244> ?p ?o ?g. }

• W2093600244 abstract "been linked to more aggressive disease and poor clinical outcomes. HER2 is particularly reliant on the chaperoning activity of heat shock protein 90 (HSP90) for its stability and function. Pharmacological blockade of HSP90 results in cellular depletion and loss of its client proteins, in turn providing a means to simultaneously disrupt multiple oncogenic pathways. Ganetespib is a clinically advanced small molecule inhibitor of HSP90. Here, we have evaluated the antitumor activity and efficacy of ganetespib, both as a single agent and in combination with clinically approved drugs, in models of human gastric cancer. Material and Methods: Cell viability was determined by CellTiterGlo. The anticancer effect of ganetespib as single agent or coupled with other chemotherapeutic agents was examined via immunoblot, immunofluorescence, flow cytometry and xenograft models in SCID mice. Results: Ganetespib demonstrated potent in vitro cytotoxic activity in a panel of 22 gastric cancer cell lines in vitro, with an average IC50 value 20 nM. The panel included 3 HER2-overexpressing (HER2+) lines and antiproliferative activity was independent of p53 status. At the molecular level, ganetespib treatment promoted destabilization of multiple HSP90 client proteins and effectors, including HER2, EGFR, IGF-IR, cMET, cKit, P-AKT, P-ERK1/2 and a number of cell cycle modulators, which ultimately resulted in apoptosis. These effects of ganetespib were durable, with kinetic analysis showing client suppression was maintained for over 48 hours following a 1 hour drug exposure. Combinations of ganetespib with chemotherapeutic agents (doxorubicin, docetaxel, cisplatin) as well as the dual HER2/EGFR kinase inhibitor lapatinib promoted significant increases in total cell death in comparison to monotherapy. Synergistic effects were also observed when ganetespib was combined with the PI3K/mTOR inhibitor BEZ235, due in part to ganetespibs’ ability to overcome the rebound in AKT activity that arises from PI3K/mTOR inhibition. The combinatorial benefit observed in vitro translated to improved efficacy in vivo, where combinations of ganetespib with capecitabine or docetaxel induced tumor regressions in NCI-N87 xenografts. Conclusions: Taken together, these data highlight the potent antitumor activity of ganetespib for gastric cancer cells, including HER2+ lines, both in vitro and in animal models. The findings support the potential therapeutic value of ganetespib, particularly in combination with standardof-care agents, for the treatment of patients with gastric cancer." @default.
• W2093600244 created "2016-06-24" @default.
• W2093600244 creator A5011899504 @default.
• W2093600244 creator A5016566105 @default.
• W2093600244 creator A5022092205 @default.
• W2093600244 creator A5027680666 @default.
• W2093600244 creator A5031256348 @default.
• W2093600244 creator A5053692136 @default.
• W2093600244 creator A5062822105 @default.
• W2093600244 creator A5073192934 @default.
• W2093600244 creator A5082347575 @default.
• W2093600244 creator A5085889953 @default.
• W2093600244 creator A5090658656 @default.
• W2093600244 date "2014-11-01" @default.
• W2093600244 modified "2023-10-17" @default.
• W2093600244 title "586 Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors" @default.
• W2093600244 doi "https://doi.org/10.1016/s0959-8049(14)70712-9" @default.
• W2093600244 hasPublicationYear "2014" @default.
• W2093600244 type Work @default.
• W2093600244 sameAs 2093600244 @default.
• W2093600244 citedByCount "0" @default.
• W2093600244 crossrefType "journal-article" @default.
• W2093600244 hasAuthorship W2093600244A5011899504 @default.
• W2093600244 hasAuthorship W2093600244A5016566105 @default.
• W2093600244 hasAuthorship W2093600244A5022092205 @default.
• W2093600244 hasAuthorship W2093600244A5027680666 @default.
• W2093600244 hasAuthorship W2093600244A5031256348 @default.
• W2093600244 hasAuthorship W2093600244A5053692136 @default.
• W2093600244 hasAuthorship W2093600244A5062822105 @default.
• W2093600244 hasAuthorship W2093600244A5073192934 @default.
• W2093600244 hasAuthorship W2093600244A5082347575 @default.
• W2093600244 hasAuthorship W2093600244A5085889953 @default.
• W2093600244 hasAuthorship W2093600244A5090658656 @default.
• W2093600244 hasConcept C104317684 @default.
• W2093600244 hasConcept C121608353 @default.
• W2093600244 hasConcept C126322002 @default.
• W2093600244 hasConcept C185592680 @default.
• W2093600244 hasConcept C190283241 @default.
• W2093600244 hasConcept C205260736 @default.
• W2093600244 hasConcept C2775932338 @default.
• W2093600244 hasConcept C2776202225 @default.
• W2093600244 hasConcept C2776694085 @default.
• W2093600244 hasConcept C2777329042 @default.
• W2093600244 hasConcept C2777560012 @default.
• W2093600244 hasConcept C2778239845 @default.
• W2093600244 hasConcept C2778305200 @default.
• W2093600244 hasConcept C2779786085 @default.
• W2093600244 hasConcept C2781303535 @default.
• W2093600244 hasConcept C502942594 @default.
• W2093600244 hasConcept C530470458 @default.
• W2093600244 hasConcept C53227056 @default.
• W2093600244 hasConcept C55493867 @default.
• W2093600244 hasConcept C64927066 @default.
• W2093600244 hasConcept C71924100 @default.
• W2093600244 hasConcept C75217442 @default.
• W2093600244 hasConcept C98274493 @default.
• W2093600244 hasConceptScore W2093600244C104317684 @default.
• W2093600244 hasConceptScore W2093600244C121608353 @default.
• W2093600244 hasConceptScore W2093600244C126322002 @default.
• W2093600244 hasConceptScore W2093600244C185592680 @default.
• W2093600244 hasConceptScore W2093600244C190283241 @default.
• W2093600244 hasConceptScore W2093600244C205260736 @default.
• W2093600244 hasConceptScore W2093600244C2775932338 @default.
• W2093600244 hasConceptScore W2093600244C2776202225 @default.
• W2093600244 hasConceptScore W2093600244C2776694085 @default.
• W2093600244 hasConceptScore W2093600244C2777329042 @default.
• W2093600244 hasConceptScore W2093600244C2777560012 @default.
• W2093600244 hasConceptScore W2093600244C2778239845 @default.
• W2093600244 hasConceptScore W2093600244C2778305200 @default.
• W2093600244 hasConceptScore W2093600244C2779786085 @default.
• W2093600244 hasConceptScore W2093600244C2781303535 @default.
• W2093600244 hasConceptScore W2093600244C502942594 @default.
• W2093600244 hasConceptScore W2093600244C530470458 @default.
• W2093600244 hasConceptScore W2093600244C53227056 @default.
• W2093600244 hasConceptScore W2093600244C55493867 @default.
• W2093600244 hasConceptScore W2093600244C64927066 @default.
• W2093600244 hasConceptScore W2093600244C71924100 @default.
• W2093600244 hasConceptScore W2093600244C75217442 @default.
• W2093600244 hasConceptScore W2093600244C98274493 @default.
• W2093600244 hasLocation W20936002441 @default.
• W2093600244 hasOpenAccess W2093600244 @default.
• W2093600244 hasPrimaryLocation W20936002441 @default.
• W2093600244 hasRelatedWork W1808605164 @default.
• W2093600244 hasRelatedWork W1879519488 @default.
• W2093600244 hasRelatedWork W1976681308 @default.
• W2093600244 hasRelatedWork W2011116859 @default.
• W2093600244 hasRelatedWork W2027677304 @default.
• W2093600244 hasRelatedWork W2028574076 @default.
• W2093600244 hasRelatedWork W2042976627 @default.
• W2093600244 hasRelatedWork W2057102041 @default.
• W2093600244 hasRelatedWork W2074407850 @default.
• W2093600244 hasRelatedWork W2151834271 @default.
• W2093600244 hasRelatedWork W2300422020 @default.
• W2093600244 hasRelatedWork W2403500327 @default.
• W2093600244 hasRelatedWork W2473218606 @default.
• W2093600244 hasRelatedWork W2591034283 @default.
• W2093600244 hasRelatedWork W2657503393 @default.
• W2093600244 hasRelatedWork W2773191561 @default.
• W2093600244 hasRelatedWork W2981036811 @default.
• W2093600244 hasRelatedWork W3039226949 @default.

• next